Product Description
ISO chemical factory,stable supplying, competitive price
AI Product Description
*The following content is generated by AI and is for reference only.
Baricitinib, often associated with the brand name Olumiant and historically linked to INTS research initiatives, is a potent, selective oral inhibitor of Janus kinase (JAK) 1 and JAK2 enzymes. Its molecular formula is C₁₆H₁₉N₅O₂, and it carries the CAS Registry Number 867490-31-5. Structurally, this compound belongs to the pyrazolo[3,4-d]pyrimidine class, designed specifically to modulate the signaling pathways of cytokines that drive inflammation. By blocking JAK1 and JAK2, Baricitinib effectively inhibits the phosphorylation of STAT proteins, thereby preventing the transcription of pro-inflammatory genes. This mechanism makes it highly effective in treating autoimmune disorders where immune dysregulation plays a central role.
The primary clinical application of Baricitinib is the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). It is also approved for the management of atopic dermatitis, offering relief for patients with moderate-to-severe disease who are candidates for systemic therapy. Furthermore, regulatory bodies have authorized its use for hospitalized adults with severe COVID-19 requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation, highlighting its utility in mitigating the hyperinflammatory state associated with viral infections. The drug is typically administered as a once-daily tablet, providing a convenient dosing regimen compared to injectable biologics. While generally well-tolerated, clinicians must monitor for potential adverse effects such as serious infections, malignancy, thrombosis, and laboratory abnormalities including elevated liver enzymes or cholesterol levels. As a small molecule inhibitor, Baricitinib offers distinct pharmacokinetic advantages, allowing for easy oral administration and rapid onset of action. Ongoing research continues to explore its efficacy in other inflammatory conditions, solidifying its position as a cornerstone therapy in modern immunology and rheumatology.